Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Mohan, Rajiv R ^a,b,c   Sinha, Sunilima ^a,b   Tandon, Ashish ^a,b   Gupta, Rangan ^a,b   Tovey, Jonathan C K ^a,b   Sharma, Ajay ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA CELL; CORNEA FIBROSIS; EXCIMER LASER; EXPERIMENTAL RABBIT; GENE DOSAGE; GENE EXPRESSION; GENE THERAPY; IN VIVO STUDY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OCULAR FIBROSIS; PHOTOREFRACTIVE KERATECTOMY; SAFE TISSUE SELECTIVE GENE THERAPY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; CONFOCAL MICROSCOPY; CORNEA DISEASE; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; RABBIT;

ADENO-ASSOCIATED VIRUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; CORNEAL DISEASES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; PHOTOREFRACTIVE KERATECTOMY; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79954482866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018771     Document Type: Article

References (45)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 28: 669-672.
2. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
3. Maguire AM, Simonelli F, Pierce EA, Mingozzi PughEN Jr, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
4. Herzog RW, Cao O, Srivastava A, (2010) Two decades of clinical gene therapy-success is finally mounting. Discov Med 9: 105-11.
5. Check E, (2002) A tragic setback. Nature 420: 116-118.
6. Gura T, (2001) Hemophilia. After a setback, gene therapy progresses. gingerly. Science 2 291: 1692-1697.
7. Behrens A, McDonnell PJ, (2002) Gene therapy for the prevention of corneal haze after photorefractive/phototherapeutic keratectomy excimer laser surgery. Adv Exp Med Biol 506: 1315-1321.
8. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE, (2005) Gene therapy in the cornea. Prog Retin Eye Res 24: 537-559.
9. Chen P, Yin H, Wang Y, Mi J, He W, et al. (2010) Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization. Mol Vis 16: 310-319.
10. Saghizadeh M, Kramerov AA, Yu FS, Castro MG, Ljubimov AV, (2010) Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest Ophthalmol Vis Sci 51: 1970-1980.
11. Sharma A, Ghosh A, Hansen ET, Newman JM, Mohan RR, (2010) Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res Bull 81: 273-278.
12. Williams KA, Coster DJ, (2010) Gene therapy for diseases of the cornea- a review. Clin Experiment Ophthalmol 38: 93-103.
13. Sharma A, Ghosh A, Siddapa C, Mohan RR, (2010) Ocular Surface: Gene Therapy. In: Besharse J, Dana R, Dartt DA, editors. Encyclopedia of the eye. Elsevier pp. 185-194.
14. Larkin DF, Oral HB, Ring CJ, Lemoine NR, George AJ, (1996) Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 61: 363-370.
15. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA, (2001) Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 71: 1214-1220.
16. Borras T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL, (2001) Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 3: 437-449.
17. Carlson EC, Liu CY, Yang X, Gregory M, Ksander B, et al. (2004) In vivo gene delivery and visualization of corneal stromal cells using an adenoviral vector and keratocyte-specific promoter. Invest Ophthalmol Vis Sci 45: 2194-2200.
18. Mohan RR, Possin DE, Mohan RR, Sinha S, Wilson SE, (2003) Development of genetically engineered tet HPV16-E6/E7 transduced human corneal epithelial clones having tight regulation of proliferation and normal differentiation. Exp Eye Res 77: 395-407.
19. Seitz B, Moreira L, Baktanian E, Sanchez D, Gray B, et al. (1998) Retroviral vector-mediated gene transfer into keratocytes in vitro and in vivo. Am J Ophthalmol 1998 126: 630-639.
20. Behrens A, Gordon EM, Li L, Liu PX, Chen Z, et al. (2002) Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci 43: 968-977.
21. Sharma A, Tovey JC, Ghosh A, Mohan RR, (2010) AAV serotype influences gene transfer in corneal stroma in vivo. Exp Eye Res 91: 440-448.
22. Ghosh A, Yue Y, Duan D, (2006) Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med 8: 298-305.
23. Lebherz C, Maguire A, Tang W, Bennett J, Wilson JM, (2008) Novel AAV serotypes for improved ocular gene transfer. J Gene Med 10: 375-382.
24. Ghosh A, Yue Y, Duan D, (2006) Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med 8: 298-305.
25. Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, et al. (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13: 517-527.
26. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM, et al. (2009) Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 17: 294-301.
27. Liu J, Saghizadeh M, Tuli SS, Kramerov AA, Lewin AS, et al. (2008) Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy. Mol Vis 14: 22087-22096.
28. Mohan RR, Schultz GS, Hong JW, Mohan RR, Wilson SE, (2003) Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res 76: 373-383.
29. Mohan RR, Sharma A, Cebulko TC, Tandon A, (2010) Vector delivery technique affects gene transfer in the cornea in vivo. Mol Vis 16: 2494-2501.
30. Carlson EC, Liu CY, Chikama T, Hayashi Y, Kao CW, et al. (2005) Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican. J Biol Chem 280: 25541-25547.
31. Kays WT, Piatigorsky J, (1997) Aldehyde dehydrogenase class 3 expression: identification of a cornea-preferred gene promoter in transgenic mice. Proc Natl Acad Sci U S A 94: 13594-135999.
32. Liu C, Arar H, Kao C, Kao WW, (2000) Identification of a 3.2 kb 5′-flanking region of the murine keratocan gene that directs beta-galactosidase expression in the adult corneal stroma of transgenic mice. Gene 250: 85-96.
33. West-Mays JA, Dwivedi DJ, (2006) The keratocyte: corneal stromal cell with variable repair phenotypes. Int J Biochem Cell Biol 38: 1625-31.
34. Netto MV, Mohan RR, Ambrósio R Jr, Hutcheon AE, Zieske JD, et al. (2005) Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea 24: 509-522.
35. Maltseva O, Folger P, Zekaria D, Petridou S, Masur SK, (2001) Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Invest Ophthalmol Vis Sci 42: 2490-2495.
36. Oliveira HB, Sakimoto T, Javier JA, Azar DT, Wiegand SJ, et al. (2010) VEGF Trap (R1R2) suppresses experimental corneal angiogenesis. Eur J Ophthalmol 20: 48-54.
37. Azar DT, (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104: 264-302.
38. Surace EM, Auricchio A, (2008) Versatility of AAV vectors for retinal gene transfer. Vision Res 48: 353-359.
39. Buch PK, Bainbridge JW, Ali RR, (2008) AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 15: 849-857.
40. Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, et al. (2008) Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 16: 458-465.
41. Dinculescu A, Glushakova L, Min SH, Hauswirth WW, (2005) Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 16: 649-663.
42. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM, (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
43. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, et al. (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-67.
44. Sharma A, Bettis DI, Cowden JW, Mohan RR, (2010) Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo. Mol Vis 16: 720-728.
45. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR, (2009) Trichostatin A inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci 50: 2695-2701.